Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk
Brooklyn Roasting Company is recalling 3,000 gallons of cold brew concentrate due to a botulism risk in New York and New Jersey.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 3.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Outcome review added Archynetys revisited the signal after coverage cooled.
Source diversity sample: Brooklyn Eagle · Yahoo · The Healthy @Reader's Digest · PIX11 · Fox Business.
How this dossier is built: methodology · AI policy · corrections.
📍 The outcome
Brooklyn Roasting Company recalled 3,000 gallons of cold brew concentrate sold in New York and New Jersey. The FDA issued the recall due to a possible botulism risk.
Epilogue added 44d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
What happened
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: Brooklyn Roasting Company is recalling 3,000 gallons of cold brew concentrate due to a botulism risk in New York and New Jersey.
- Predictive Outlook: Archynetys algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
The Brooklyn Roasting Company has issued a food safety recall for its cold brew concentrate. The affected product was sold across two states, New York and New Jersey.
Coverage from Fox Business, PIX11, and Yahoo emphasizes that 3,000 gallons of the product are being recalled. PIX11 reports that the FDA is involved in the action, while The Healthy @Reader's Digest notes the recall is driven by a possible botulism risk.
Future developments depend on the scope of the FDA's oversight and further updates regarding the specific batches of cold brew concentrate affected by the recall.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Who reported it (5)
- Food safety recall for Brooklyn Roasting Company’s cold brew concentrate Brooklyn Eagle · 47d ago
- 3,000 Gallons Of Cold Brew Recalled Due To Botulism Risk Yahoo · 47d ago
- Coffee Recalled in 2 States for Possible Botulism Risk The Healthy @Reader's Digest · 47d ago
- Coffee sold in NY, NJ recalled for botulism risk: FDA PIX11 · 47d ago
- Brooklyn Roasting Company recalls cold brew sold in New York and New Jersey over botulism risk Fox Business · 47d ago
Questions people are asking
Which products are being recalled?
Brooklyn Roasting Company's cold brew concentrate.
How much product is affected by the recall?
According to Yahoo, 3,000 gallons of cold brew are being recalled.
Where was the recalled coffee sold?
The product was sold in New York and New Jersey.
Topics
Related trends
FDA names acting heads of drug and vaccine centers to permanent roles
FDA solidifies leadership by making acting drug and vaccine chiefs permanent, ending interim stewardship
Tesla crashes into scaffolding in Midtown Manhattan, killing passenger
A Tesla collision with Midtown scaffolding kills a passenger and lands the driver on manslaughter charges.
A New Drug Lifts the Fog of Sleepiness for Those With Narcolepsy
A first‑in‑class orexin agonist cleared global hurdles, promising a new wake‑up call for narcolepsy sufferers.
Cream Cheese recalled after listeria detected by FDA
Thousands of cream cheese products recalled after listeria detected by FDA
Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
New research flags a 40% reduction in ovarian size for girls prenatally exposed to Tylenol, sparking scrutiny of a common pain reliever.
A breakthrough pancreatic cancer drug won approval. They still struggle to access it
FDA clears daraxonrasib, a first RAS‑targeted breakthrough for pancreatic cancer, but distribution hurdles spark a global push for similar drugs.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.